Inogen (INGN) has officially launched its Aurora CPAP mask portfolio in the United States, marking its entry into the $7.5 billion sleep apnea market. The new line comprises the F1 Full Face, N1 Nasal Cushion and P1 Nasal Pillows, designed to accommodate various facial structures and therapy requirements. With this launch, Inogen broadens its product suite beyond portable oxygen concentrators, leveraging existing distribution agreements with over 200 home medical equipment providers nationwide to accelerate time to market and deepen partnerships with key prescribers.

The Aurora masks rollout is supported by the AMG CPAP Mask Trial Study conducted in August 2025, a 30-day trial involving 140 patients on CPAP therapy for at least six months. Results showed that 87% of participants reported high overall satisfaction, citing the triple-material headgear and medical-grade silicone cushion for improved comfort and seal integrity. Inogen highlights that 92% of users experienced reduced mask-related pressure points, while quiet honeycomb vent technology led to a 15% decrease in reported sleep disturbances for bed partners.

CEO Kevin Smith stated that Aurora Masks will serve as a growth catalyst, projecting a 12% expansion in Inogen’s respiratory care revenue by fiscal 2026. The company expects the masks to contribute incremental gross margin of approximately 55%, compared with its legacy device line margin of 48%. Management plans to allocate an initial $5 million to direct-to-consumer marketing campaigns and training programs for 500 clinical field representatives, aiming to secure 10% share of the CPAP mask accessory segment within two years.